R&D service

Drug delivery & barrier permeability

Assess barrier integrity, injury and repair, then develop permeability or candidate-transport assays for the relevant tissue system.

Discuss a barrier study View the plan and evidence ↘

Bright-field and FITC microscopy in control and inflammation-challenged human intestinal organoids — Study data

Intestinal barrier evidence

Study intestinal barrier changes through permeability and IL-8

Human intestinal organoids use FITC-Dextran and IL-8 assays to investigate barrier and inflammatory changes. Candidate-specific studies can extend this work to transport, retention and barrier integrity.

Explore the experimental results View the IBD model and barrier study

Study focus

Questions we can help answer

01How well does the candidate cross the relevant tissue barrier?
02How does treatment alter barrier structure and function?
03How do imaging and functional endpoints explain delivery performance together?

Study workflow

From barrier integrity to candidate transport and effects

Measure candidate transport alongside barrier integrity and injury. Model identity and baseline function provide the context for interpreting permeability.

Barrier system and study objective

Identify the relevant interface—intestinal epithelium, blood–brain barrier or another tissue system—and whether the priority is transport, retention, injury or repair.

Model identity and baseline function

Confirm cell identity, architecture, tight junctions and baseline permeability against predefined acceptance criteria before candidate testing.

Candidate exposure and permeability

Set donor/receiver orientation, time, concentration and controls around modality, formulation and exposure route, using FITC-Dextran, tracing, imaging or project-appropriate quantification.

Transport and barrier status

Analyze permeability with viability, morphology, F-actin, ZO-1 and other junction readouts to build an integrated view of candidate transport and barrier status.

Study images and readouts

Read barrier function through permeability and junction structure

FITC-Dextran, F-actin and ZO-1 results connect permeability change with epithelial structure for candidate and formulation studies.

View image

Barrier and inflammatory readouts | FITC-positive area and mean IL-8 rose under inflammatory conditions. FITC uses matched representative fields; IL-8 has three measurements per condition.

Study dataView the IBD model and barrier study

Expected study outputs

What you receive

Barrier baseline and batch QC

Model identity, tight-junction and baseline permeability results, with batch QC criteria.

Transport and barrier-effect results

Candidate transport or retention data alongside changes in viability, structure and barrier integrity.

Study report and next steps

Methods, raw data, study conditions and recommended next experiments, including recovery or mass-balance results where applicable.

Relevant model systems

Study design

TRiCBIO intestinal organoid studies combine morphology, permeability, viability and F-actin/ZO-1 readouts, with human programs designed around the sample and candidate. Blood–brain barrier studies extend this approach through endothelial–astrocyte systems, tight-junction imaging, and readouts of permeability and candidate effects.

PROJECT DISCUSSION

Select a barrier model and permeability assays

The candidate or formulation, target barrier, exposure conditions and permeability question shape the model, controls and assay panel.

Start a study discussion See how we work ↗